Determinants of Mortality and Mid-Term Outcomes After Transcarotid Artery Revascularization and Transfemoral Carotid Artery Stenting

Abstract

Objectives:

The potential benefit of transcarotid artery revascularization (TCAR) over transfemoral carotid artery stenting (tfCAS) has been studied in the perioperative period with lower rates of stroke and death; however, data on mid-term outcomes are limited. We aimed to evaluate 3-year outcomes after TCAR and tfCAS and determine the primary predictors of 30-day and 1-year mortality following TCAR.

Methods:

Data from the Vascular Quality Initiative for patients undergoing TCAR or tfCAS from January 2016 to December 2022 were analyzed. 1:1 propensity score matching using the nearest-neighbor method was used to adjust baseline demographics and clinical characteristics. Kaplan-Meier survival analysis and Cox Proportional Hazard Regression were used to evaluate long-term outcomes. Iterative stepwise multiple logistic regression analysis and Cox Proportional Hazard Regression were used to identify predictors of 30-day and 1-year mortality, respectively, based upon preoperative, intraoperative, and postoperative factors.

Results:

A total of 70 237 patients were included in analysis (TCAR=58.7%, tfCAS=41.3%). Transcarotid artery revascularization patients were older and had higher rates of comorbid conditions and high-risk medical and anatomic features than tfCAS patients. Propensity score matching yielded 22 322 pairs with no major differences between groups except that TCAR patients were older (71.6 years vs 70.8 years). At 3 years, TCAR was associated with a 24% reduction in hazard of death compared with tfCAS (hazard ratio [HR]=0.76, 95% confidence interval [CI]=0.71-0.82, p<0.001), for both symptomatic and asymptomatic patients. This survival advantage was established in the first 6 months (HR=0.59, 95% CI=0.53-0.62, p<0.001), with no difference in mortality risk from 6 months to 36 months (HR=0.95, 95% CI=0.86-1.05, p=0.31). Transcarotid artery revascularization was also associated with decreased hazard for 3-year stroke (HR=0.81, 95% CI=0.66-0.99, p=0.04) and stroke or death (HR=0.81, 95% CI=0.76-0.87, p<0.001) compared with tfCAS. The top predictors for 30-day and 1-year mortality were postoperative complications. The primary independent predictor was the occurrence of postoperative stroke.

Conclusions:

Transcarotid artery revascularization had a sustained mid-term survival advantage associated over tfCAS, with the benefit being established primarily within the first 6 months. Notably, our findings highlight the importance of postoperative stroke as the primary independent predictor for 30-day and 1-year mortal.

Clinical Impact

The ongoing debate over the superiority of TCAR compared to tfCAS and CEA has been limited by a lack of comparative studies examining the impact of pre-operative symptoms on outcomes. Furthermore, data are scarce on mid-term outcomes for TCAR beyond the perioperative period. As a result, it remains uncertain whether the initial benefits of stroke and death reduction observed with TCAR over tfCAS persist beyond one year. Our study addresses these gaps in the literature, offering evidence to enable clinicians to assess the efficacy of TCAR for up to three years. Additionally, our study seeks to identify risk factors for postoperative mortality following TCAR, facilitating optimal patient stratification

Keywords

common carotid artery carotid stent/stenting endovascular treatment/therapy embolic protection flow-diverting stent/technology

Get full access to this article

View all access options for this article.

References

van Velzen

Kuhrij

Westendorp

, et al. Prevalence, predictors and outcome of carotid stenosis: a sub study in the Preventive Antibiotics in Stroke Study (PASS). BMC Neurol. 2021;21(1):20. doi:10.1186/s12883-020-02032-4.

Ferguson

Eliasziw

Barr

, et al. The North American symptomatic carotid endarterectomy trial: surgical results in 1415 patients. Stroke. 1999;30(9):1751–1758. doi:10.1161/01.str.30.9.1751.

Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet. 1998;351(9113):1379–1387.

Bonati

Kakkos

Berkefeld

, et al. European Stroke Organisation guideline on endarterectomy and stenting for carotid artery stenosis. Eur Stroke J. 2021;6(2):I-XLVII. doi:10.1177/23969873211012121.

AbuRahma

Avgerinos

Chang

, et al. Society for Vascular Surgery clinical practice guidelines for management of extracranial cerebrovascular disease. J Vasc Surg. 2022;75(1S):4S–22S. doi:10.1016/j.jvs.2021.04.073.

Tedesco

Lee

Dalman

, et al. Postprocedural microembolic events following carotid surgery and carotid angioplasty and stenting. J Vasc Surg. 2007;46(2):244–250. doi:10.1016/j.jvs.2007.04.049.

Brott

Hobson

II Howard

, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med. 2010;363(1):11–23. doi:10.1056/NEJMoa0912321. Erratum in: N Engl J Med. 2010;363(5):498. Erratum in: N Engl J Med. 2010;363(2):198.

Gupta

Corriere

Dodson

, et al. The incidence of microemboli to the brain is less with endarterectomy than with percutaneous revascularization with distal filters or flow reversal. J Vasc Surg. 2011;53(2):316–322. doi:10.1016/j.jvs.2010.08.063.

Huibers

Calvet

Kennedy

, et al. Mechanism of procedural stroke following carotid endarterectomy or carotid artery stenting within the International Carotid Stenting Study (ICSS) randomised trial. Eur J Vasc Endovasc Surg. 2015;50(3):281–288. doi:10.1016/j.ejvs.2015.05.017.

10.

Malas

Leal Lorenzo

Nejim

, et al. Analysis of the ROADSTER pivotal and extended-access cohorts shows excellent 1-year durability of transcarotid stenting with dynamic flow reversal. J Vasc Surg. 2019;69(6):1786–1796. doi:10.1016/j.jvs.2018.08.179.

11.

Kashyap

Schneider

Foteh

, et al. Early outcomes in the ROADSTER 2 study of transcarotid artery revascularization in patients with significant carotid artery disease. Stroke. 2020;51(9):2620–2629. doi:13.1161/STROKEAHA.120.030550.

12.

Kwolek

Jaff

Leal

, et al. Results of the ROADSTER multicenter trial of transcarotid stenting with dynamic flow reversal. J Vasc Surg. 2015;62(5):1227–1234. doi:10.1016/j.jvs.2015.04.460.

13.

Malas

Dakour-Aridi

Kashyap

, et al. TransCarotid revascularization with dynamic flow reversal versus carotid endarterectomy in the vascular quality initiative surveillance project. Ann Surg. 2022;276(2):398–403. doi:10.1097/SLA.0000000000004496.

14.

Schermerhorn

Liang

Eldrup-Jorgensen

, et al. Association of transcarotid artery revascularization vs transfemoral carotid artery stenting with stroke or death among patients with carotid artery stenosis. JAMA. 2019;322(23):2313–2322. doi:10.1001/jama.2019.18441.

15.

Kragsterman

Björck

Lindbäck

, et al. Long-term survival after carotid endarterectomy for asymptomatic stenosis. Stroke. 2006;37(12):2886–2891. doi:10.1161/01.STR.0000248967.44015.88.

16.

Yang

Zhu

, et al. Long-term efficacy and safety of carotid artery stenting versus endarterectomy: a meta-analysis of randomized controlled trials. PLoS ONE. 2017;12(7):e0180804. doi:10.1371/journal.pone.0180804. Erratum in: PLoS ONE. 2018;13(8):e0202932.

17.

Gurm

Yadav

Fayad

, et al. Long-term results of carotid stenting versus endarterectomy in high-risk patients. N Engl J Med. 2008;358(15):1572–1579. doi:10.1056/NEJMoa0708028.

18.

Malas

Elsayed

Naazie

, et al. Propensity score-matched analysis of 1-year outcomes of transcarotid revascularization with dynamic flow reversal, carotid endarterectomy, and transfemoral carotid artery stenting. J Vasc Surg. 2022;75(1):213–222.e1. doi:10.1016/j.jvs.2021.07.242.

19.

Columbo

Martinez-Camblor

Stone

, et al. Procedural safety comparison between transcarotid artery revascularization, carotid endarterectomy, and carotid stenting: perioperative and 1-year rates of stroke or death. J Am Heart Assoc. 2022;11(19):e024964. doi:10.1161/JAHA.121.024964.

20.

Halliday

Harrison

Hayter

, et al. 10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial. Lancet. 2010;376(9746):1074–1084. doi:10.1016/S0140-6736(10)61197-X.

21.

Khuri

Henderson

DePalma

, et al. Determinants of long-term survival after major surgery and the adverse effect of postoperative complications. Ann Surg. 2005;242(3):326–341; discussion 341–343. doi:10.1097/01.sla.0000179621.33268.83.

22.

Kashyap

Schneider

, et al. One-year outcomes after transcarotid artery revascularization (TCAR) in the ROADSTER 2 trial. J Vasc Surg. 2022;76(2):466–473.e1. doi:10.1016/j.jvs.2022.03.872.

23.

Galyfos

Tsoutsas

Konstantopoulos

, et al. Editor’s choice—early and late outcomes after transcarotid revascularisation for internal carotid artery stenosis: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg. 2021;61(5):725–738. doi:10.1016/j.ejvs.2021.01.039.

24.

Turner

Zhu

Rao

, et al. Carotid stenosis patients with a remote history of cerebrovascular events have increased risk of major adverse events over asymptomatic patients. J Vasc Surg. 2022;76(6):1625–1632. doi:10.1016/j.jvs.2022.07.013.

25.

Wong

Warner

Schroeder

, et al. Risk of surgery and anesthesia for ischemic stroke. Anesthesiology. 2000;92(2):425–432. doi:10.1097/00000542-200002000-00024.

26.

Simons

Goodney

Baril

, et al. The effect of postoperative stroke and myocardial infarction on long-term survival after carotid revascularization. J Vasc Surg. 2013;57(6):1581–1588. doi:10.1016/j.jvs.2012.11.118.

27.

Guo

Tong

, et al. Three-year clinical results of carotid artery stenting in treating patients with contralateral carotid artery occlusion. J Stroke Cerebrovasc Dis. 2018;27(5):1296–1301. doi:10.1016/j.jstrokecerebrovasdis.2017.12.016.

28.

Halliday

Bulbulia

Bonati

, et al. Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy. Lancet. 2021;398(10305):1065–1073. doi:10.1016/S0140-6736(21)01910-3.

29.

Stonko

Goldsborough

III Kibrik

, et al. Use of transcarotid artery revascularization, transfemoral carotid artery stenting, and carotid endarterectomy in the US from 2015 to 2019. JAMA Netw Open. 2022;5(9):e2231944. doi:10.1001/jamanetworkopen.2022.31944.

30.

Naylor

Rantner

Ancetti

, et al. Editor’s choice: European Society for Vascular Surgery (ESVS) 2023 clinical practice guidelines on the management of atherosclerotic carotid and vertebral artery disease. Eur J Vasc Endovasc Surg. 2023;65(1):7–111. doi:10.1016/j.ejvs.2022.04.011.